Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterol­aemia: TULiPS (Turkish Lipid Study)

References

• Steinberg D, Gotto AM, Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA 1999;282:2043–50
   Google Scholar
• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269–76
   PubMed Web of Science ®Google Scholar
• Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005;165:725–30
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57
   Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–22
   Google Scholar
• Corsini A, Jacobson TA, Ballantyne CM. Fluvastatin: clinical and safety profile. Drugs 2004;64:1305–23
   Google Scholar
• Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, et al. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005;21:231–44
   PubMed Web of Science ®Google Scholar
• Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study (LCAS)). Am J Cardiol 1997;80:278–86
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024–31
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215–22
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Riegger G, Moore N, et al. Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther 2004;18:67–75
   PubMed Web of Science ®Google Scholar
• Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999;144:263–70
   PubMed Web of Science ®Google Scholar
• Bruckert E, Verpilleux MP, Dejager S, Isaacsohn J. Comparison of efficacy and safety assessment of fluvastatin in patients < 65 years versus > or = 65 years of age. Am J Cardiol 2005;96: 1142–8
   PubMed Web of Science ®Google Scholar
• Sabia H, Prasad P, Smith HT, et al. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 2001;37:502–11
   PubMed Web of Science ®Google Scholar
• Barilla D, Prasad P, Hubert M, Gumbhir-Shah K. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. Biopharm Drug Dispos 2004;25:51–9
   Google Scholar
• Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43–9
   Google Scholar
• Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998;80: 1–34
   Google Scholar
• Ballantyne CM, Pazzucconi F, Pinto X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001;23:177–92
   PubMed Web of Science ®Google Scholar
• Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1–10
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• de Maat MP, Trion A. C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol 2004;15:651–7
   PubMed Web of Science ®Google Scholar
• Grundy SM. Low-density lipoprotein, non-high-density lipo-protein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526–9
   PubMed Web of Science ®Google Scholar
• Isaacsohn JL, LaSalle J, Chao G, Gonasun L. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. Clin Ther 2003;25:904–18
   PubMed Web of Science ®Google Scholar
• Insull W, Marais AD, Aronson A, Manfreda S, and the Fluvastatin Study Group. Efficay and safety of fluvastatin ER 80 mg compared with fluvastatin IR 40 mg in the treatment of primary hypercholesterolemia. Br. J. Cardiol 2004;11:148–55
   Google Scholar
• Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933–5
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230–5
   Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015–23
   PubMed Web of Science ®Google Scholar
• Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66–9B
   Google Scholar
• Ballantyne CM, McKenney J, Trippe BS. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol 2000;86:759–63
   Google Scholar
• Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 2003;22:151–4
   PubMed Web of Science ®Google Scholar
• Turk S, Yildiz A, Tukek T, et al. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study. Int Urol Nephrol 2001;32:713–16
   PubMedGoogle Scholar
• Teramoto T, Goto Y, Kurokawa K, et al. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients. Am J Cardiol 1995;76:33–6A
   Google Scholar
• Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999;10:435–41
   PubMed Web of Science ®Google Scholar
• Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84:149–61, ix
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–80
   PubMed Web of Science ®Google Scholar
• Topol EJ. Intensive statin therapy – a sea change in cardiovascular prevention. N Engl J Med 2004;350:1562–4
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–8
   PubMed Web of Science ®Google Scholar
• van Haelst PL, van Doormaal JJ, May JF, et al. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med 2001;12: 503–9
   PubMedGoogle Scholar
• Cortellaro M, Cofrancesco E, Boschetti C, et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. Thromb Haemost 2000;83:549–53
   PubMed Web of Science ®Google Scholar
• Sniderman AD. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol 2004;15:433–8
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553–64
   PubMed Web of Science ®Google Scholar
• Benghozi R, Bortolini M, Jia Y, et al. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002;89:231–3
   PubMed Web of Science ®Google Scholar
• Corsini A. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. Int J Clin Pract 2004;58:494–503
   PubMed Web of Science ®Google Scholar